FGFR2 as a molecular target in endometrial cancer
Byron, Sara A. & Pollock, Pamela M. (2009) FGFR2 as a molecular target in endometrial cancer. Future Oncology, 5(1), pp. 27-32.
|Published Version (PDF 6Mb) |
Administrators only | Request a copy from author
Although molecularly targeted therapies have been effective in some cancer types, no targeted therapy is approved for use in endometrial cancer. The recent identification of activating mutations in fibroblast growth factor receptor 2 (FGFR2) in endometrial tumors has generated a new avenue for the development of targeted therapeutic agents. The majority of the mutations identified are identical to germline mutations in FGFR2 and FGFR3 that cause craniosynostosis and hypochondroplasia syndromes and result in both ligand-independent and ligand-dependent receptor activation. Mutations that predominantly occur in the endometrioid subtype of endometrial cancer, are mutually exclusive with KRAS mutation, but occur in the presence of PTEN abrogation. In vitro studies have shown that endometrial cancer cell lines with activating FGFR2 mutations are selectively sensitive to a pan-FGFR inhibitor, PD173074. Several agents with activity against FGFRs are currently in clinical trials. Investigation of these agents in endometrial cancer patients with activating FGFR2 mutations is warranted.
Citation countsare sourced monthly fromand citation databases.
These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science generally from 1980 onwards.
Citations counts from theindexing service can be viewed at the linked Google Scholar™ search.
|Item Type:||Journal Article|
|Keywords:||Antineoplastic Agents/pharmacology, Clinical Trials as Topic, Endometrial Neoplasms/drug therapy/ genetics, Female, Humans, Mutation, Pyrimidines/pharmacology, Receptor, Fibroblast Growth Factor, Type 2/ genetics|
|Subjects:||Australian and New Zealand Standard Research Classification > MEDICAL AND HEALTH SCIENCES (110000) > ONCOLOGY AND CARCINOGENESIS (111200) > Cancer Cell Biology (111201)|
|Divisions:||Past > Schools > Cell & Molecular Biosciences|
Past > QUT Faculties & Divisions > Faculty of Science and Technology
Current > Institutes > Institute of Health and Biomedical Innovation
|Copyright Owner:||Copyright 2009 Future Medicine Ltd.|
|Deposited On:||09 Sep 2011 15:14|
|Last Modified:||20 Nov 2012 08:15|
Repository Staff Only: item control page